Eli Lilly (United States)
Impact in
- Psychiatry and Mental health top 0.5%
- Schizophrenia research and treatment
-
- Diabetes Treatment and Management
Papers in
-
- Schizophrenia research and treatment 512
-
- Diabetes Treatment and Management 727
- Top scholars
- Mark L. HeimanRay W. FullerFrank P. BymasterDarryle D. SchoeppSteven WrightonMatthias H. TschöpLian YuDonald R. Gehlert
- Journals
- Journal of Clinical Oncology (391 papers)Journal of Pharmaceutical Sciences (358 papers)Bioorganic & Medicinal Chemistry Letters (247 papers)Tetrahedron Letters (244 papers)Journal of Medicinal Chemistry (236 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Eli Lilly (United States)
20.3k papers receiving 887.3k citations
Peers
Comparison fields: 5 of 247
- Psychiatry and Mental health 96.4k
- Endocrinology, Diabetes and Metabolism 88.3k
- Biological Psychiatry 13.0k
- Endocrine and Autonomic Systems 32.5k
- Cellular and Molecular Neuroscience 92.9k
Countries citing scholars working at Eli Lilly (United States)
This map shows the geographic impact of research produced by authors working at Eli Lilly (United States). It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Eli Lilly (United States) with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli Lilly (United States) more than expected).
Fields of papers published by authors at Eli Lilly (United States)
This network shows the impact of papers affiliated with Eli Lilly (United States) at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Eli Lilly (United States) at the time of their publication.
About Eli Lilly (United States)
In recent decades, authors affiliated with Eli Lilly (United States) have published 22.9k papers, which have received a total of 1.0M indexed citations . Scholars at this organization have produced 1.9k papers in Psychiatry and Mental health, 1.9k papers in Endocrinology, Diabetes and Metabolism, 1.8k papers in Pharmacology, 1.8k papers in Cellular and Molecular Neuroscience and 2.1k papers in Oncology on the topics of Neuroscience and Neuropharmacology Research (916 papers), Receptor Mechanisms and Signaling (902 papers), Diabetes Treatment and Management (727 papers), Neurotransmitter Receptor Influence on Behavior (594 papers), Analytical Chemistry and Chromatography (564 papers), Statistical Methods in Clinical Trials (549 papers), Schizophrenia research and treatment (512 papers) and Health Systems, Economic Evaluations, Quality of Life (511 papers). Their work is cited by papers focused on Psychiatry and Mental health (96.4k citations), Endocrinology, Diabetes and Metabolism (88.3k citations), Biological Psychiatry (13.0k citations), Endocrine and Autonomic Systems (32.5k citations) and Cellular and Molecular Neuroscience (92.9k citations). Authors at Eli Lilly (United States) collaborate with scholars in United States, United Kingdom and Germany and have published in prestigious journals including Journal of Clinical Oncology, Journal of Pharmaceutical Sciences, Bioorganic & Medicinal Chemistry Letters, Tetrahedron Letters and Journal of Medicinal Chemistry. Some of Eli Lilly (United States)'s most productive authors include Mark L. Heiman, Ray W. Fuller, Frank P. Bymaster, Darryle D. Schoepp, Steven Wrighton, Matthias H. Tschöp, Lian Yu, Donald R. Gehlert, Alan Y. Chiang and Michael J. Pikal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.